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Abstract
Background: The clinical diagnosis of encephalitis is often difficult and identification of a causative organism is
infrequent. The encephalitis syndrome may herald the emergence of novel pathogens with outbreak potential.
Individual treatment and an effective public health response rely on identifying a specific pathogen. In Australia
there have been no studies to try to improve the identification rate of encephalitis pathogens. This study aims to
review the diagnostic assessment of adult suspected encephalitis cases.
Methods: A retrospective clinical audit was performed, of all adult encephalitis presentations between July 1998
and December 2007 to the three hospitals with adult neurological services in the Hunter New England area,
northern New South Wales, Australia. Case notes were examined for evidence of relevant history taking, clinical
features, physical examination, laboratory and neuroradiology investigations, and outcomes.
Results: A total of 74 cases were included in the case series. Amongst suspected encephalitis cases, presenting
symptoms and signs included fever (77.0%), headache (62.1%), altered consciousness (63.5%), lethargy (32.4%),
seizures (25.7%), focal neurological deficits (31.1%) and photophobia (17.6%). The most common diagnostic
laboratory test performed was cerebrospinal fluid (CSF) analysis (n = 67, 91%). Herpes virus polymerase chain
reaction (n = 53, 71.6%) and cryptococcal antigen (n = 46, 62.2%) were the antigenic tests most regularly
performed on CSF. Neuroradiological procedures employed were computerized tomographic brain scanning (n =
68, 91.9%) and magnetic resonance imaging of the brain (n = 35, 47.3%). Thirty-five patients (47.3%) had
electroencephalograms. The treating clinicians suspected a specific causative organism in 14/74 cases (18.9%), of
which nine (12.1%) were confirmed by laboratory testing.
Conclusions: The diagnostic assessment of patients with suspected encephalitis was not standardised. Appropriate
assessment is necessary to exclude treatable agents and identify pathogens warranting public health interventions,
such as those transmitted by mosquitoes and those that are vaccine preventable. An algorithm and guidelines for
the diagnostic workup of encephalitis cases would assist in optimising laboratory testing so that clinical
management can be best tailored to the pathogen, and appropriate public health measures implemented.
Background
Encephalitis is an uncommon but important clinical and
public health syndrome. Clinically, the diagnosis is fre-
quently difficult, treatments are limited and outcomes
often include serious morbidity or death [1]. From a
public health viewpoint, encephalitis is a syndrome that
can herald the emergence of novel pathogens with out-
break potential [2] and it is not currently under routine
surveillance in Australia. Of significance to both clini-
cians and public health specialists is that pathogen iden-
tification in the majority of cases of encephalitis remains
elusive [3,4].
Encephalitis is defined as inflammation of the brain
parenchyma and presents with clinical evidence of brain
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dysfunction [5-7]. The classic clinical encephalitis triad
is “headache, fever and altered consciousness” with a
range of other possible clinical symptoms, including
focal neurological signs, seizures and altered behaviour
[8,9]. Diagnosis is based on a combination of clinical
features, laboratory tests and neuroradiological imaging
[6,7,10].
Infectious encephalitis can be caused by numerous
pathogens that vary by geographical location. Viruses are
the most common causative agents with herpes simplex
virus (HSV) the most regularly implicated in developed
countries [11,12]. A complete list of potential pathogens
is difficult to compile, but has been attempted [8,13,14].
Diagnosis of the causative agent is important for treat-
ment, prognosis and public health interventions. Effective
treatment is available for some bacterial and parasitic
pathogens, as well as herpes simplex virus, where treat-
ment with acyclovir reduces mortality from 70% to 20-
30% [15,16]. For many other pathogens treatment is sup-
portive, however, prognosis differs by causative agent [6].
The public health response depends on the geographic
location but in Australia early detection of certain causa-
tive pathogens, such as Murray Valley Encephalitis
(MVE), Australian Bat Lyssavirus (ABL), Kunjin virus,
and Hendra virus would lead to measures aimed at limit-
ing further transmission in the community [2].
Pathogen identification rates for patients hospitalised
with encephalitis vary between countries, but have been
reported in 40% of hospitalised patients in the United
States (US) [17] and 20-40% of encephalitis related
deaths in the US [18] and United Kingdom (UK) [19].
In NSW, a review of 18 years of hospital data found
that only 30% of encephalitis patients were discharged
with a pathogen diagnosis [4]. Forty-eight percent of
encephalitis related deaths in Australia have a pathogen
diagnosis [3].
In Australia there have been no studies to try to
improve the identification rate of encephalitis pathogens
and there is currently no widely accepted diagnostic
algorithm to guide clinicians in their workup. The Infec-
tious Diseases Society of America (IDSA) published
guidelines for the management of encephalitis in 2008
which included a standardised diagnostic evaluation, but
the relevance in Australia needs to be determined [20].
The Health Protection Agency (HPA) guidelines for the
investigation of viral encephalitis in the UK are currently
under review [21] and the HPA is leading a multi-centre
prospective study to assess the aetiology of encephalitis
in England. A recent study from France suggested that a
standardised approach to pathogen diagnosis may
improve the pathogen identification rate [22].
This study aims to review the diagnostic work-up cur-
rently performed by clinicians investigating suspected
adult encephalitis cases in Australia.
Methods
Adult encephalitis cases were identified at the John Hun-
ter, Maitland and Tamworth Regional Referral Hospitals,
which provide all referral neurological services for the
Hunter and New England areas of northern New South
Wales (NSW) (population 814,146), from July 1998-
December 2007 using the NSW Health hospital statistics
database. The database was searched using all ICD-10
codes pertaining to encephalitis. The search selected only
patients ≥ 18 years who were admitted to hospital and
given a primary discharge code for encephalitis. Cases
were excluded if the treating physician documented that
the case did not have encephalitis at the time of discharge
(coding error), if the patient was transferred to another
facility (other than one involved in the study) prior to a
diagnostic work-up being performed, if the case had
transverse myelitis (a shared encephalitis code), or if an
encephalitis diagnosis was already made prior to admis-
sion, negating the need for a diagnostic work-up.
The patient records of suspected encephalitis cases
were individually reviewed by one of two members of
the research team (both clinicians), using a specially
designed audit tool (CH, YG). Information was extracted
regarding: length of hospitalisation, Intensive Care Unit
(ICU) stay and ventilatory support (as appropriate),
signs and symptoms at the time of admission, relevant
exposure history, laboratory and neuroimaging results,
the clinical diagnosis and outcome (using the Glasgow
Outcome Scale) at the end of the episode of care. If a
patient chart was difficult to read or interpret, consen-
sus regarding the finding was reached between these
two researchers. Laboratory and neuroimaging results
were sought in hospital’s computerised databases as well
as in the patient record.
Signs and symptoms at time of admission
The following clinical signs and symptoms were
recorded for each case: headache, fever, altered con-
sciousness (including irritability and/or coma), lethargy,
seizures, abnormal behaviour, focal neurological signs,
neck stiffness, rash, photophobia, myalgia and/or
arthralgia. Signs and symptoms were recorded in the
patient record as present “at presentation” if there was a
record of their presence within the first 48 hours of
admission or the patient/next of kin reported them in
the 24 hours prior to admission.
History of relevant exposures/risk factors
Each patient record was searched for a documented his-
tory of the following: occupation, overseas travel,
domestic travel, contact with animals, exposure to
insects, contact with bats, water sports/water exposure,
and other exposures considered relevant to the treating
clinicians.
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Laboratory results
All blood tests, lumbar puncture, brain biopsy and
autopsy results were recorded as performed or not per-
formed, and whether the outcome led to a pathogen
diagnosis. Additionally, the CSF result was recorded as
consistent with viral encephalitis if the result demon-
strated raised WCC, with > 50% monocytes, raised pro-
tein and normal glucose [23].
All testing performed to attempt to identify a specific
pathogen was recorded. Tests for specific pathogens per-
formed were compared to a predetermined list of 27
“possible encephalitis pathogens”. The list of “possible
encephalitis pathogens” of relevance in an Australian
setting was compiled by the authors, who formed a
Reference Panel, chosen for their expertise in neurology,
microbiology, and/or public health.
Neuroimaging results
For each case of encephalitis, a record of all investiga-
tions by computerized tomography (CT) and magnetic
resonance imaging (MRI) was recorded. It was further
documented whether the result was “consistent with
encephalitis” based on the radiology report.
Electroencephalogram (EEG)
For each case, EEGs performed were recorded and
whether the result was consistent with encephalitis.
Clinical diagnosis
Each patient record was examined to determine the final
diagnosis made by the treating clinician. Where possible,
the discharge summary was used for this purpose.
Where a discharge summary was not available, the final
notes recorded by treating clinicians were reviewed to
determine the final diagnosis. Where the clinician had
ascribed a particular pathogen as the cause of the
patient’s encephalitis, this was noted and compared to
the relevant laboratory findings.
Outcome (using the Glasgow Outcome Scale)
Outcome for each case of suspected encephalitis was
recorded using the Glasgow Outcome Scale, as either
normal (GOS category 5), disabled (GOS categories 2, 3,
4) or deceased (GOS category 1).
Ethics
Ethical approval was given by the Hunter New England
and the Australian National University Human Research
Ethics Committees.
Results
A total of 104 adult patients with a discharge diagnosis of
encephalitis were admitted to the John Hunter Hospital,
Maitland Hospital and the Tamworth Regional Referral
Hospital between July 1998 and December 2007. Their
encephalitis ICD-10 codes are shown in Table 1. Thirty
patients were excluded from our study due to: coding
errors (12 cases), transfer to another facility prior to diag-
nostic work-up (2 cases), transverse myelitis (13 cases),
and encephalitis diagnosis made prior to admission
(3 cases). Of the 74 cases included, 42 were from the
John Hunter Hospital, 18 from the Maitland Hospital
and 14 from the Tamworth Regional Referral Hospital.
The median age of cases was 49.2 years (IQR 35.5-
65.5) and 41 cases (55%) were male. There were no
apparent geographical clusters of cases by postcode, nor
was there a difference in admission rates by season (or
month). The mean length of stay was 12 days (range 1-
Table 1 ICD-10 code diagnosis and the number of cases with a laboratory confirmed pathogen diagnosis
ICD-10 Code Code name Cases Pathogen confirmed by laboratory test
Codes for “known” pathogens
A321 Listerial meningitis & meningoencephalitis 3 3
A858 Other specified viral encephalitis 3 2
B004 Herpesviral encephalitis 10 2
B011 Varicella encephalitis 1 1
B020 Zoster encephalitis 3 1
G052 Encephalitis, myelitis & encephalomyelitis-other infectious and parasitic diseases 1 0
G040 Acute disseminated encephalitis 1 N/A
Subtotal for “known” pathogens 22 9
Codes for “unknown” pathogens
G048 Other encephalitis, myelitis and encephalomyelitis 1 N/A
G049 Encephalitis, myelitis and encephalomyelitis, unspecified 10 N/A
A86 Unspecified viral encephalitis 41 N/A
Subtotal ("unknown” pathogens) 52 N/A
Grand Total 74 9
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63 days), with 26/74 (35%) patients requiring an ICU
admission and 17/74 (23%) ventilatory support.
History of relevant exposures/risk factors
An occupational history was documented in 44/74
(57.5%) cases, a history of domestic travel in 16/74
(20.0%) cases, overseas travel in 10/74 (12.5%) cases,
exposure to animals in 9/74 (11.3%) cases and exposure
to water sports in 1/74 cases (1.5%). Exposure to insects
and/or bats was not recorded for any patient and other
relevant encephalitis risk factor histories were either not
elicited or documented very infrequently in patient notes.
Signs and symptoms at time of admission
The classical encephalitis triad of headache, fever and
altered conscious state (including coma and/or irritabil-
ity) was present in 26/74 (35.1%) cases (Table 2).
Neuroimaging
A CT brain was performed in 68/74 cases (91.9%) and
an MRI brain in 35/74 cases (47.3%). Two of the CT
scans and eight of the MRI scans were reported as “con-
sistent with encephalitis”.
Electroencephalogram
An EEG was done in 36/74 cases (48.6%), of which only
four showed focal temporal lobe activity consistent with
Herpes simplex encephalitis. Two of these patients had
corresponding MRI abnormalities.
Laboratory tests
A CSF sample was taken from 67/74 patients (90.5%)
with encephalitis. Twenty-nine of these 67 cases (43.3%
of the total) had both a high monocyte count and raised
protein, consistent with viral encephalitis. Table 1 shows
the ICD10 codes for the cases (n = 9) for which a
laboratory test confirmed the discharge diagnosis.
Table 3 records the specific encephalitis pathogens for
which tests were ordered on CSF or blood, as appropri-
ate, and their relative frequency. The average number of
tests ordered for the study patients was three per patient.
Outcome (using the Glasgow Outcome Scale, GOS)
Four patients in our study died during their hospital
stay, 25/74 (33.8%) cases were “disabled” (GOS 2, 3 or
4) at the time of their discharge and 40/74 (54.1%) were
classified as “normal” (GOS 5). There were five cases for
which a decision regarding their GOS outcome could
not be made due to missing information in their patient
record.
Discussion
This hospital audit found that the investigation of sus-
pected adult encephalitis cases in northern NSW, Aus-
tralia by a specialised neurological service was not
standardised. Relevant patient history that would assist
diagnostic investigation was seldom recorded in the
patient record and only a limited number of pathogens
were commonly sought.
Documented history taking in medical records
reflected inadequate exploration of many potential ence-
phalitis risk factors. Although this may have been asked,
there was no formal record excluding important risk
exposures. This may represent missed opportunities for
assisting with pathogen diagnosis and/or public health
action.
Table 2 Signs and symptoms “at presentation"* for all hospitalised adult encephalitis cases in three Hunter New
England hospitals, Australia, July 1998-December 2007
Symptoms at presentation Cases, n = 74 (%)
Fever 57 (77.0%)
Altered Consciousness State (ACS) including irritability and/or coma 51 (68.9%)
Headache 46 (62.1%)
Encephalitis “triad”
(headache, fever, ACS)
26 (35.1%)
Other symptoms:
Lethargy 24 (32.4%)
Focal neurological signs 23 (31.1%)
Seizures 19 (25.7%)
Photophobia 13 (17.6%)
Neck stiffness 11 (14.9%)
Abnormal behaviour 9 (12.1%)
Rash 7 (9.5%)
Myalgia and/or arthralgia 2 (2.7%)
*a sign/symptom was considered to be present “at presentation” if the patient/next of kin reported to have had the sign/symptom in the 24 hours prior to
presentation or if it was documented in the patient record during the first 48 hours of their admission.
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These audit results found that the majority of the 27
pathogens, which the multidisciplinary Reference Group
considered important to exclude in patients with sus-
pected encephalitis in Australia, were tested for infre-
quently, with each patient having an average of only
three specific pathogen tests done. The most commonly
tested pathogens were HSV and Cryptococcus, presum-
ably because these pathogens are easily tested and
amenable to treatment. Among the nine patients with
identified pathogens, herpesviruses were the leading
viral cause identified in our study (two cases due to
HSV and one case of varicella zoster virus), possibly
reflecting the frequency of testing. Three cases were
found to be due to Listeria, with no other bacterial
cause for encephalitis found. Whether an expanded
standardised testing regime would identify more causa-
tive organisms warrants further investigation.
Fever, headache and altered consciousness were the
most common presenting symptoms in patients with
encephalitis but the clinical triad [8,9] of all three features
was only seen in 26/74 (35.1%) patients. Seizures (25.7%)
and focal neurological signs (35.1%) were the other rela-
tively frequent presenting clinical features. Thus nearly
two thirds of these patients with possible encephalitis
presented with a variable constellation of symptoms mak-
ing this syndrome a diagnostic challenge. Other condi-
tions, particularly autoimmune encephalitis may present
with a clinical picture similar to viral encephalitis [24].
Although there were only four deaths in the study
population, 25 patients (33.8%) had significant disability
at discharge from hospital with a Glasgow Outcome
Scale of 2, 3 or 4. Incidence and severity of neurological
sequelae vary depending on the aetiological agent caus-
ing encephalitis [6]. As there was a low rate of pathogen
identification, this study is unable to speculate about
clinical severity of different pathogens.
In general, studies of coded hospital discharge data
have shown a poor rate of encephalitis pathogen diagno-
sis [4,17,19]. Our hospital audit found that although 22/
74 (30%) cases had a “known” pathogen ICD-10 code,
the number of laboratory confirmed pathogen diagnoses
was fewer; 22 cases had an ICD-10 code for a “known
pathogen”, however, only 9/22 (41% of patients with
“known” pathogen codes) actually had a laboratory con-
firmed specific pathogen diagnosis. Thus more than 85%
of cases had no specific aetiology confirmed. This find-
ing casts doubt on previous studies of hospital coded
data, suggesting that the true rate of pathogen diagnosis
could be much lower than that reported. This highlights
the need to explore the use of a suitable clinical algo-
rithm for the diagnosis of encephalitis cases. The guide-
line would need to be regionally verified, given the
unique pathogens found in Australia. It has been sug-
gested that such regional guidelines would enhance
pathogen diagnosis rates and may lead to the discovery
of novel infectious and non-infectious entities [25].
There are several weaknesses inherent in a retrospective
study of this nature. Although we report on the medical
history of each encephalitis patient and the symptomatol-
ogy at time of presentation, our findings are limited to
information from the patients’ records. Certainly some
aspects of history may have been taken and some symp-
toms or signs may have been present, but not recorded in
the patient record. Since the study covers a 10-year period
the increased availability of molecular diagnostic methods
may have resulted in a systematic change in diagnostic
approaches. In addition there would be value in confirm-
ing these findings in a larger multi-centre study.
Table 3 Specific encephalitis pathogens and frequency of testing
Viral pathogens Testing frequency, n = 74 (%) Bacterial pathogens Testing frequency, n = 74 (%)
Adenovirus 5 (6.8%) Bartonella sp 1 (1.4%)
Australian Bat Lyssavirus 0 Chlamydia species 5 (6.8%)
Cytomegalovirus 18 (24.3%) Legionella pneumonia 4 (5.4%)
Enterovirus group 20 (27.0%) Mycoplasma pneumoniae 9 (12.2%)
Epstein-Barr virus 16 (21.6%) Q fever 10 (13.5%)
Flavivirus 11 (14.9%)
Herpes simplex virus 53 (71.6%) Other pathogens Testing frequency, n = 74 (%)
Influenza A & B viruses 6 (8.1%) Cryptococcus 46 (62.2%)
Japanese Encephalitis 0 Mycobactrium tuberculosis 11 (14.9%)
Kunjin 2 (2.7%) Rickettsiae 2 (2.7%)
Measles virus 1 (1.4%) Toxoplasma 7 (9.5%)
Mumps virus 0
Murray Valley Encephalitis 5 (6.8%)
Rubella 2 (2.7%)
Varicella zoster virus 14 (18.9%)
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Conclusions
Encephalitis is a serious disease with consequences not only
to the individual, but specific encephalitis-causing pathogens
have significant public health implications. From a clinical
perspective, it is important to exclude treatable agents, such
as Herpes virus and Cryptococcus in all patients. It would
also be useful to exclude other common causes of encephali-
tis. From a public health perspective, some pathogens have
particular significance to the wider community and warrant
public health interventions, such as those transmitted by
mosquitoes (MVE, kunjin, flavivirus) and bats (ABL), and
those that are vaccine preventable (influenza, mumps,
measles, rubella). Australia may benefit from guidelines to
aid clinicians in making a diagnosis of specific pathogens
causing encephalitis. An important next line of research
would be to formulate and trial an algorithm for diagnostic
work-up. If such an algorithm still delivers low pathogen
diagnostic yield, it would be important to consider novel
testing techniques to search for new pathogens.
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